Claims
- 1. A triazole compound of formula I whereinA is a straight-chain or branched C1-C18-alkylene group, or a straight chain or branched group consisting of 1 to 18 methylene members and one or two members selected from the group consisting of O, S, NR3, NR3CO, COO, OCO, C3-C6-cycloalkylene, a double bond and a triple bond, X is R1 is H, CO2R3, NR3R4, OR4, C3-C6-cycloalkyl or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen; R2 has the meanings indicated for R1 or is CF3, SR3, halogen or CN; R3 is H or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl, phenyl or halogen; R4 has the meanings indicated for R3 or is COR3 or CO2R3; Ar is an optionally fused phenyl ring selected from the group consisting of phenyl, naphthalene, dihydronaphthalene, tetrahydronaphthalene, quinoline, dihydroquinoline, tetrahydroquinoline, indole, dihydroindole, benzimidazole, benzothiazole, benzothiadiazole, benzopyrrole and benzotriazole, and which optionally fused phenyl ring is unsubstituted or carries from one to four substituents selected from the group consisting of: OR4, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, halogen, CN, CO2R3, NO2, SO2R3, SO3R3, NR3R4, SO2NR3R4, SR3, CF3, CHF2, C3-C6-cycloalkyl, phenyl, naphthalene, pyrrolidine, piperidine, morpholine, piperazine, pyridine, pyrimidine, triazine, pyrrole, thiophene, thiazole, imidazole, oxazole, isoxazole, pyrazole and thiadiazole, wherein each of the cyclic substituents is unsubstituted or substituted by C1-C8-alkyl, halogen, OC1-C8-alkyl, OH, NO2 or CF3, or a salt thereof with a physiologically tolerated acid.
- 2. The compound of formula I defined in claim 1, wherein the optionally fused phenyl ring is selected from the group consisting of phenyl, naphthalene, dihydronaphthalene, tetrahydronaphthalene, quinoline, dihydroquinoline, tetrahydroquinoline, indole, dihydroindole and benzothiazole.
- 3. The compound of formula I defined in claim 1, wherein the optionally fused phenyl ring is unsubstituted or carries from one to four substituents selected from the group consisting of: OR4, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, halogen, CN, CO2R3, NO2, SO2R3, SO3R3, NR3R4, SO2NR3R4, SR3, CF3, CHF2, C3-C6-cycloalkyl, phenyl, naphthalene, pyrrolidine, piperidine, morpholine, pyrrole, thiophene and imidazole.
- 4. The compound of formula I defined in claim 1, wherein the optionally fused phenyl ring is selected from the group consisting of phenyl, naphthalene, dihydronaphthalene, tetrahydronaphthalene, quinoline, dihydroquinoline, tetrahydroquinoline, indole, dihydroindole and benzothiazole, and which optionally fused phenyl ring is unsubstituted or carries from one to four substituents selected from the group consisting of: OR4, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, halogen, CN, CO2R3, NO2, SO2R3, SO3R3, NR3R4, SO2NR3R4, SR3, CF3, CHF2, C3-C6-cycloalkyl, phenyl, naphthalene, pyrrolidine, piperidine, morpholine, pyrrole, thiophene and imidazole, wherein each of the cyclic substituents is unsubstituted or substituted by C1-C8-alkyl, halogen, OC1-C8-alkyl, OH, NO2 or CF3.
- 5. The compound of formula I defined in claim 1, wherein the optionally fused phenyl ring Ar is selected from the group consisting of phenyl, naphthalene, dihydronaphthalene and tetrahydronaphthalene, and which optionally fused phenyl ring is unsubstituted or carries from one to four substituents selected from the group consisting of: OR4, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, halogen, CN, CO2R3, NO2, SO2R3, SO3R3, NR3R4, SO2NR3R4, SR3, CF3, CHF2, C3-C6-cycloalkyl, phenyl, naphthalene, pyrrolidine, piperidine, morpholine, piperazine, pyridine, pyrimidine, triazine, pyrrole, thiophene, thiazole, imidazole, oxazole, isoxazole, pyrazole and thiadiazole, wherein each of the cyclic substituents is unsubstituted or substituted by C1-C8-alkyl, halogen, OC1-C8-alkyl, OH, NO2 or CF3.
- 6. The compound of formula I defined in claim 1, wherein Ar is a phenyl ring which is unsubstituted or substituted by from one to four substituents selected from the group consisting of: OR4, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, halogen, CN, CO2R3, NO2, SO2R3, SO3R3, NR3R4, SO2NR3R4, SR3, CF3, CHF2, C3-C6-cycloalkyl, phenyl, naphthalene, pyrrolidine, piperidine, morpholine, piperazine, pyridine, pyrimidine, triazine, pyrrole, thiophene, thiazole, imidazole, oxazole, isoxazole, pyrazole and thiadiazole, wherein each of the cyclic substituents is unsubstituted or substituted by C1-C8-alkyl, halogen, OC1-C8-alkyl, OH, NO2 or CF3.
- 7. The compound of formula I defined in claim 1 whereinR1 is H, CO2R3, NR3R4, OR4 or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen; R3 is H or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen; and wherein the optionally fused phenyl ring is unsubstituted or carries one or two substituents selected from the group consisting of: OR4, C1-C8-alkyl, halogen, CN, CO2R3, NO2, SO2R3, SO3R3, NR3R4, SO2NR3R4, SR3, CF3, CHF2, C3-C6-cycloalkyl, phenyl, naphthalene, pyrrolidine, piperidine, morpholine, piperazine, pyridine, pyrimidine, triazine, pyrrole, thiophene, thiazole, imidazole, oxazole, isoxazole, pyrazole and thiadiazole, wherein each of the cyclic substituents is unsubstituted or substituted by C1-C8-alkyl, halogen, OC1-C8-alkyl, OH, NO2 or CF3.
- 8. The compound of formula I defined in claim 5 whereinR1 is H, CO2R3, NR3R4, OR4 or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen; R3 is H or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen; and wherein the optionally fused phenyl ring is unsubstituted or carries one or two substituents selected from the group consisting of: OR4, C1-C8-alkyl, halogen, CN, CO2R3, NO2, SO2R3, SO3R3, NR3R4, SO2NR3R4, SR3, CF3, CHF2, C3-C6-cycloalkyl, phenyl, naphthalene, pyrrolidine, piperidine, morpholine, piperazine, pyridine, pyrimidine, triazine, pyrrole, thiophene, thiazole, imidazole, oxazole, isoxazole, pyrazole and thiadiazole, wherein each of the cyclic substituents is unsubstituted or substituted by C1-C8-alkyl, halogen, OC1-C8-alkyl, OH, NO2 or CF3.
- 9. The compound of the formula I defined in claim 1 wherein A is C1-C10-alkylene or a group consisting of 1 to 10 methylene members and one or two radicals selected from the group consisting of O, S, NR3, cyclohexylene, a double bond and a triple bond.
- 10. The compound of the formula I defined in claim 5 wherein A is C1-C10-alkylene or a group consisting of 1 to 10 methylene members and one or two radicals selected from the group consisting of O, S, NR3, cyclohexylene, a double bond and a triple bond.
- 11. The compound of the formula I defined in claim 5 whereinR1 is H or OR4, where R4 is H, C3-C6-cycloalkyl or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen; R2 is H, C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen, or NR3R4, where R3 and R4 are, independently of one another, H, phenyl-C1-C8-alkyl or C1-C8-alkyl, or OR4 where R4 is H or C1-C8-alkyl, or CF3; and Ar is phenyl which is unsubstituted or carries one, two, three or four substituents selected from the group consisting of C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen, or OR4 where R4 is H, C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen, or CHF2, CF3, CN, halogen, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, phenyl, naphthalene, pyrrolidine, piperidine, morpholine, piperazine, pyridine, pyrimidine, triazine, pyrrole, thiophene, thiazole, imidazole, oxazole, isoxazole, pyrazole and thiadiazole.
- 12. The compound of the formula I defined in claim 5 whereinR1 is H or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen; R2 is H, C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen, or NR3R4 where R3 and R4 are, independently of one another, H or C1-C8-alkyl, or OR4 where R4 is H or C1-C8-alkyl, or CF3; A is C1-C10-alkylene or a group consisting of 1 to 10 methylene members and one member selected from the group consisting of oxygen, sulfur and NR3; Ar is phenyl which is unsubstituted or carries from one to four substituents selected from the group consisting of: CN, SR3, halogen, C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen, or phenyl, naphthalene, OR4, NO2, NR3R4, CHF2 and CF3.
- 13. The compound of the formula I defined in claim 12 whereinA is SC3-C10-alkylene, OC3-C10-alkylene or NR3-C3-C10-alkylene, where R3 is H or C1-C8-alkyl; R1 is H or C1-C8-alkyl; Ar is phenyl which is unsubstituted or carries from one to four substituents selected from the group consisting of C1-C8-alkyl, OC1-C8-alkyl, CHF2, CF3 and CN.
- 14. The compound of the formula I defined in claim 13 wherein the phenyl ring Ar is substituted by one or two substituents which are located in position 3 and position 5, with one substituent being CF3, CHF2 or C1-C8-alkyl and the other substituent being H or C1-C8-alkyl.
- 15. The compound of the formula I defined in claim 1 whereinR1 is H or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen, R2 is H, NR3R4 or OR4 where R3 and R4 are, independently of one another, H, C1-C8-alkyl or phenyl-C1-C8-alkyl; A is C1-C10-alkylene or is a group consisting of 1 to 10 methylene members and one or two members selected from the group consisting of O, S, NR3 where R3 is H or C1-C8-alkyl, a double bond and a triple bond.
- 16. The compound of the formula I defined in claim 5 whereinR1 is H or C1-C8-alkyl which is unsubstituted or substituted by OH, OC1-C8-alkyl or halogen, R2 is H, NR3R4 or OR4 where R3 and R4 are, independently of one another, H, C1-C8-alkyl or phenyl-C1-C8-alkyl; A is C1-C10-alkylene or is a group consisting of 1 to 10 methylene members and one or two members selected from the group consisting of O, S, NR3 where R3 is H or C1-C8-alkyl, a double bond and a triple bond.
- 17. A pharmaceutical composition containing the compound of formula I defined in claim 13 and a conventional pharmaceutical aid.
- 18. A method for treating a disorder which responds to dopamine D3 receptor ligands, which comprises administering an effective amount of the compound of formula I defined in claim 1 to a person requiring such treatment.
- 19. The method of claim 18, wherein the disorder which responds to dopamine D3 receptor ligands is schizophrenia, depression, a neurosis or a psychosis.
Parent Case Info
This application is a divisional application of U.S. application Ser. No. 08/765,916 (allowed), filed Jan. 14, 1997, under 35 U.S.C. §371 as a national stage application of Internation Application No. PCT/EP 95/02,781, which was filed Jul. 14, 1995.
US Referenced Citations (8)
Number |
Name |
Date |
Kind |
4338453 |
Gall et al. |
Jul 1982 |
A |
4408049 |
Gall et al. |
Oct 1983 |
A |
4487773 |
Temple, Jr. et al. |
Dec 1984 |
A |
4575555 |
Temple et al. |
Mar 1986 |
A |
4577020 |
Gall et al. |
Mar 1986 |
A |
4613600 |
Gammans et al. |
Sep 1986 |
A |
4711885 |
Wierzbicki et al. |
Dec 1987 |
A |
4886805 |
Bru-Magniez et al. |
Dec 1989 |
A |
Foreign Referenced Citations (4)
Number |
Date |
Country |
0199641 |
Oct 1986 |
EP |
0254623 |
Jan 1988 |
EP |
0568437 |
Nov 1993 |
EP |
1053085 |
Dec 1966 |
GB |
Non-Patent Literature Citations (4)
Entry |
Czarnocka-Janowicz et al, Chemical Abstrasts vol. 115 Entry 49519 (1991).* |
Sokoloff et al., Nature 347, pp. 146-151 (Sep. 1990). |
Reitz et al., J. Med. Chem. 37, pp. 1060-1062 (1994). |
Milan et al., J. Pharm. Exp. Therapeutics 275, 885-898 (1995). |